Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Xinlei CaiKey Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China.ORCID https://orcid.org/0009-0005-4295-6371
Yi YeState Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai, China.
Xiaoping LiuKey Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China.ORCID https://orcid.org/0000-0002-3246-4227
Zhaoyuan FangZhejiang University-University of Edinburgh Institute, Zhejiang University School of Medicine, Haining, China.
Luonan ChenKey Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China.
Fei LiDepartment of Pathology and Frontier Innovation Center, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Hongbin JiKey Laboratory of Systems Health Science of Zhejiang Province, School of Life Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, China.ORCID https://orcid.org/0000-0003-0891-6390
Funding
Chinese Academy of Sciences Basic Frontier Scientific Research Program ZDBS-LY-SM006Innovative research team of high-level local universities in Shanghai SSMU-ZLCX20180500National Key Research and Development Program of China 2020YFA0803300National Key Research and Development Program of China 2022YFA1103900National Natural Science Foundation of China 32293192National Natural Science Foundation of China 82030083National Natural Science Foundation of China 82141101National Natural Science Foundation of China 82341002National Natural Science Foundation of China 82372794
6 · The paper itself
Abstract
The inconsistency of the association between genes and cancer prognosis is often attributed to many variables that contribute to patient survival. Whether there exist the
Indexed as
Lung NeoplasmsMitosisNeoplasmsAdenocarcinoma of LungBiomarkers, TumorBreast NeoplasmsCell Line, TumorClass I Phosphatidylinositol 3-KinasesGene Expression Regulation, NeoplasticHumansMutationPrognosisSurvival AnalysisBiomarkers, TumorClass I Phosphatidylinositol 3-Kinasescancer biologyGEARGene Steadily Associated with Prognosishub geneshumanimmuneMEMORYmitosisMulti-gradient Permutation Survival Analysis
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Multi-gradient permutation survival analysis identifies mitosis and immune signatures steadily associated with cancer patient prognosis. · full record | OpenQuestion